Truist Securities Lowers HCA Healthcare Price Target While Maintaining Buy Rating

Key Facts

HCA Healthcare Inc. shares closed down 3.23% on April 28 as investor concerns mounted over declining patient volumes. Operational metrics revealed significant weakness in respiratory-related admissions and emergency room visits, alongside a drop in both inpatient and outpatient surgery volumes. While management reaffirmed its 2026 earnings guidance, the absence of an upward revision to full-year 2024 targets and heavy reliance on Medicaid programs fueled market apprehension. This decline follows Truist Securities' decision to lower its price target to $535 from $546, joining firms like Oppenheimer and Stephens in adjusting their outlooks. Analysts suggest that while headwinds such as seasonal respiratory trends are transitory, the recent operational data has weighed heavily on sentiment. Investors remain focused on whether the company can recover its surgical momentum to meet its reaffirmed annual guidance.

Version History